Tranzyme Overview
- Year Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
14
- Latest Deal Type
-
M&A
- Investors
-
2
Tranzyme General Information
Description
Developer of small molecule therapeutics for the treatment of acute and chronic gastrointestinal or GI, motility disorders.
Contact Information
Website
www.tranzyme.comCorporate Office
- 5001 South Miami Boulevard
- Suite 300
- Durham, NC 27703
- United States
Corporate Office
- 5001 South Miami Boulevard
- Suite 300
- Durham, NC 27703
- United States
Tranzyme Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 15-Jul-2013 | Completed | Clinical Trials - Phase 2 | |||
| 8. IPO | 04-Apr-2011 | Completed | Clinical Trials - Phase 2 | |||
| 7. Mezzanine | 31-Dec-2010 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC (Series B) | 15-Jun-2010 | Completed | Generating Revenue | |||
| 5. Debt - General | 01-Jun-2009 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 01-Feb-2008 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 01-Nov-2007 | Completed | Product Development | |||
| 2. Early Stage VC (Series A) | 13-May-2005 | $32.5M | $38.5M | Completed | Product Development | |
| 1. Early Stage VC | 18-Dec-2003 | $6M | $6M | Completed | Startup |
Tranzyme Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 69,300,000 | $0.000010 | $1 | $1 | 1x | $1 | 64.82% |
Tranzyme Patents
Tranzyme Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2003217695-A1 | Novel trans-viral vectors comprising multicistronic expression constructs and methods of use | Inactive | 22-Feb-2002 | ||
| WO-2003072797-A1 | Novel trans-viral vectors comprising multicistronic expression constructs and methods of use | Inactive | 22-Feb-2002 | ||
| US-20030167500-A1 | Integrating nucleotide sequences into genomes of vertebrates by contacting plasma membrane of isolated early stage embryo (fertilized ooctyes) with vector | Inactive | 21-Dec-2001 | ||
| AU-2002367024-A1 | Methods and compositions for generating a genetically modified animal using lentiviral vectors | Inactive | 21-Dec-2001 | ||
| CA-2470527-A1 | Methods and compositions for generating a genetically modified animal using lentiviral vectors | Inactive | 21-Dec-2001 | A01K67/0275 |
Tranzyme Signals
Tranzyme Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BDC Capital | Growth/Expansion | Minority | ||
| Desjardins Capital | PE/Buyout | Minority | ||
| Fonds de solidarite FTQ | PE/Buyout | Minority | ||
| Greer Capital Advisors | Venture Capital | Minority | ||
| H.I.G. HealthBridge Partners | Growth/Expansion | Minority |
Tranzyme Acquisitions (1)
Tranzyme’s most recent deal was a Reverse Merger with Ocera Therapeutics. The deal was made on 15-Jul-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Ocera Therapeutics | 15-Jul-2013 | Reverse Merger | Biotechnology |
Tranzyme FAQs
-
When was Tranzyme founded?
Tranzyme was founded in 1998.
-
Where is Tranzyme headquartered?
Tranzyme is headquartered in Durham, NC.
-
What is the size of Tranzyme?
Tranzyme has 14 total employees.
-
What industry is Tranzyme in?
Tranzyme’s primary industry is Pharmaceuticals.
-
Is Tranzyme a private or public company?
Tranzyme is a Private company.
-
What is Tranzyme’s current revenue?
The current revenue for Tranzyme is .
-
How much funding has Tranzyme raised over time?
Tranzyme has raised $165M.
-
Who are Tranzyme’s investors?
BDC Capital, Desjardins Capital, Fonds de solidarite FTQ, Greer Capital Advisors, and H.I.G. HealthBridge Partners are 5 of 13 investors who have invested in Tranzyme.
-
When was Tranzyme acquired?
Tranzyme was acquired on 15-Jul-2013.
-
Who acquired Tranzyme?
Tranzyme was acquired by Ocera Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process